Life Science Partner recruits senior biotechnology entrepreneurial and Co-Founder and Chairman of North Carolina Innovation Foundation.
Life Science Partner announces the recruitment of Max Wallace, a biotechnology CEO and innovative leader, to lead Accelerate Brain Cancer Cure, Inc. ABC2 is a not-for-profit organization established in 2001 with a for-profit mindset and a singular focus: to hasten the discovery of a cure for brain cancer. Founded by the Case , the ABC2 has an entrepreneurial model of identifying and funding critical research into brain cancer and catalyzing interdisciplinary collaboration works. Wallace shares the ABC2 passion for using a not-for-profit model for pushing forward new drug development – particularly to treat diseases ignored by big pharma companies due to low prevalence and smaller markets.
Max Wallace is Chief Executive Officer of TheraLogics, an early-stage biopharmaceutical company based on technology developed by Dr. Albert Baldwin at the University of North Carolina. He previously co-founded and served as President of Trimeris, a public biopharmaceutical company that created and brought to market the world’s first entry inhibitor, establishing a new class of drugs for HIV/AIDS and other viral diseases. He also founded and developed several other biopharmaceutical companies, including Sphinx Pharmaceuticals Corporation (now a division of Eli Lilly & Co); SARCO (now a part of PPD/Pharmaco); and Cogent Neuroscience.
“Max is a dynamic leader who knows how to bring a team together and motivate them around a common goal,” noted Tom Callaway, MD, founder and president of Life Science Partner. “He will bring his exceptional entrepreneurial instincts and innovative not-for-profit expertise together to provide the visionary and strategic leadership needed to fulfill ABC’s important mission.”
Wallace received his Bachelors degree Duke University and earned his law degree from the University of Florida College of Law in Gainesville, Florida.